Iloperidone for the treatment of schizophrenia

Drugs of Today

Volumn 46, Issue 8, 2010, Pages 567-579

  Bishop, Jeffrey R ^a,b   Bishop, D L ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUNO LIKE 4; CERAMIDE KINASE; CILIARY NEUROTROPHIC FACTOR; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DOPAMINE 2 RECEPTOR; DRUG METABOLITE; FLUOXETINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR ALPHA2; GLUTAMATE RECEPTOR IONOTROPIC AMPA4 PROTEIN; HALOPERIDOL; HISTAMINE H1 RECEPTOR; ILOPERIDONE; KETOCONAZOLE; MUSCARINIC M1 RECEPTOR; NPAS3 PROTEIN; PAROXETINE; PROLACTIN; PROTEIN; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 7 RECEPTOR; SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY MEMBER 3A1; TENASCIN R; UNCLASSIFIED DRUG; UNINDEXED DRUG; XK KELL BLOOD GROUP COMPLEX SUBUNIT RELATED FAMILY MEMBER 4; ZIPRASIDONE; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE;

AKATHISIA; AREA UNDER THE CURVE; BINDING AFFINITY; BLURRED VISION; BODY TEMPERATURE; BRIEF PSYCHIATRIC RATING SCALE; CHEMICAL STRUCTURE; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; CONSTIPATION; DIABETES MELLITUS; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TRANSFORMATION; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; INCREASED APPETITE; INTRAOCULAR PRESSURE; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MENTAL PATIENT; NOSE CONGESTION; OBESITY; ORTHOSTATIC HYPOTENSION; PHARMACOGENOMICS; PHASE 3 CLINICAL TRIAL (TOPIC); POSITIONAL DIZZINESS; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; REVIEW; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; STEADY STATE; SWEATING; TACHYCARDIA; TARDIVE DYSKINESIA; TRIACYLGLYCEROL BLOOD LEVEL; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA; ANIMAL; DRUG INTERACTION; EVIDENCE BASED MEDICINE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PSYCHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; ISOXAZOLES; PHARMACOGENETICS; PIPERIDINES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 79952110999     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.8.1509989     Document Type: Review

References (24)

1. Mutlib, A.E., Klein, J.T. Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther 1998, 286(3): 1285-93. (Pubitemid 29135541)
2. Mutlib, A.E., Strupczewski, J.T., Chesson, S.M. Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone. Drug Metab Dispos 1995, 23(9): 951-64.
3. Fanapt Prescribing Information. Novartis Pharmaceuticals Corporation 2010.
4. Kalkman, H.O., Subramanian, N., Hoyer, D. Extended radioligand binding profile of iloperidone: A broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001, 25(6): 904-14. (Pubitemid 34031895)
5. Subramanian, N., Kalkman, H.O. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26(3): 553-60. (Pubitemid 34252950)
6. Sainati, S.M., Hubbard, J.W., Chi, E., Grasing, K., Brecher, M.B. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. J Clin Pharmacol 1995, 35(7): 713-20.
7. Baroldi, P., Wolfgang, C., Fisher, D. A pharmacokinetic (PK)-pharmacodynamic (PD) relationship exists for efficacy of iloperidone, a novel investigational atypical antipsychotic agent. 160th Annu Meet Am Psychiatr Assoc (May 19-24, San Diego) 2007, Abst NR507.
8. Glassman, A.H., Bigger, J.T. Antipsychotic drugs: Prolonged QTc interval, Torsade de Points, and sudden death. Am J Psychiatry 2001, 158(11): 1774-82. (Pubitemid 33054769)
9. Potkin, S.G., Litman, R.E., Torres, R., Wolfgang, C.D. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. J Clin Psychopharmacol 2008, 28(2, Suppl. 1): S4-11.
10. Risperdal Prescribing Information. Ortho-McNeil Janssen, LLC 2010.
11. Hamilton, J., Wolfgang, C., Feeney, J., Baroldi, P., Polymeropoulos, M. Efficacy of iloperidone is comparable to risperidone in analyses of a placebo- and risperidone-controlled clinical trial for schizophrenia. 162nd Annu Meet Am Psychiatr Assoc (May 16-21, San Francisco) 2009, Abst NR1-033.
12. Feeney, J., Wolfgang, C., Polymeropoulos, M., Baroldi, P., Hamilton, J. The comparative efficacy of iloperidone and haloperidol across four short-term trials. 162nd Annu Meet Am Psychiatr Assoc (May 16-21, San Francisco) 2009, Abst NR1-026.
13. Kemmler, G., Hummer, M., Widschwendter, C., Fleischhacker, W.W. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: A meta-analysis. Arch Gen Psychiatry 2005, 62(12): 1305-12.
14. Cutler, A.J., Kalali, A.H., Weiden, P.J., Hamilton, J., Wolfgang, C.D. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008, 28(2, Suppl. 1): S20-8.
15. Kane, J.M., Lauriello, J., Laska, E., Di Marino, M., Wolfgang, C.D. Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008, 28(2, Suppl. 1): S29-35.
16. Weiden, P.J., Cutler, A.J., Polymeropoulos, M.H., Wolfgang, C.D. Safety profile of iloperidone: A pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008, 28 (2, Suppl. 1): S12-9.
17. Lavedan, C., Licamele, L., Volpi, S. et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 2009, 14(8): 804-19.
18. Volpi, S., Potkin, S.G., Malhotra, A.K., Licamele, L., Lavedan, C. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009, 70(6): 801-9.
19. Volpi, S., Heaton, C., Mack, K. et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 2009, 14(11): 1024-31.
20. Lavedan, C., Volpi, S., Wolfgang, C. A ciliary neurotrophic factor (CNTF) polymorphism affects iloperidone treatment response in a phase III clinical trial. 161st Annu Meet Am Psychiatr Assoc (May 3-8, Washington DC) 2008, Abst NR5-061.
21. Thompson, A., Lavedan, C., Volpi, S. Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry Res 2010, 175(3): 271-3.
22. Wolfgang, C., Polymeropoulos M. Single-nucleotide polymorphisms in the CYP2D6 gene are correlated with iloperidone drug exposure levels, impacting the degree of QTc prolongation associated with iloperidone treatment. 57th Annu Meet Am Soc Human Genet (October 23-27, San Diego) 2007, Abst 1040/T.
23. Hill, C.L., Phadke, D., Boyce, K.M. Four-week iloperidone depot injectable: Safety and pharmacokinetic profile in patients with schizophrenia and schizoaffective disorder. 161st Annu Meet Am Psychiatr Assoc (May 3-8, Washington DC) 2008, Abst NR4-022.
24. Kongsamut, S., Roehr, J.E., Cai, J. et al. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol 1996, 317(2-3): 417-23. (Pubitemid 27014051)